Pharmaceutical technology company XtalPi announced a collaboration with US drug maker Eli Lilly on Tuesday. The partnership will focus on using AI and robotics in drug discovery, with a significant upfront payment of up to $250 million. As part of this collaboration, XtalPi will utilize its ID4Inno™ small-molecule drug discovery platform, combining AI, autonomous labs, and expert domain knowledge enabling innovative and efficient drug discovery processes. The collaboration will also leverage autonomous robotic workstations for chemical synthesis and assays. XtalPi has operations in both China and the US, with various research and development centers across major Chinese cities. [TechNode reporting]
Related
